UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Practical guidance for the management of aromatase inhibitor-associated bone loss

Annals of oncology, 2008-08, Vol.19 (8), p.1407-1416

2008

Volltextzugriff (PDF)

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

European journal of cancer (1990), 2009-03, Vol.45 (4), p.608-617

2009

Volltextzugriff (PDF)

F9 Adjuvant chemotherapy for elderly women with breast cancer: immediate benefit and long-term risk

Critical reviews in oncology/hematology, 2009, Vol.72 (1), p.S9-S10

Aapro, M.S

2009

Volltextzugriff (PDF)

Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Annals of oncology, 2019-10, Vol.30, p.v722

2019

Volltextzugriff (PDF)

1765P - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Annals of oncology, 2019-10, Vol.30, p.v722-v722

2019

Volltextzugriff (PDF)

Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma

Annals of oncology, 2000-03, Vol.11 (3), p.301-306

2000

Volltextzugriff (PDF)

2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan

Annals of oncology, 2023-10, Vol.34, p.S1093-S1094

2023

Volltextzugriff (PDF)

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

Annals of oncology, 2023-10, Vol.34, p.S330-S330

2023

Volltextzugriff (PDF)

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force

Critical reviews in oncology/hematology, 2007-04, Vol.62 (1), p.62-73

2007

Volltextzugriff (PDF)

PCN16 Disease Burden and Treatment outcomes in Second-Line Therapy of Patients with Estrogen-Receptor Positive (ER+) Advanced Breast Cancer: A Review of the Literature

Value in health, 2011, Vol.14 (7), p.A436-A436

2011

Volltextzugriff (PDF)

3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials

European journal of cancer (1990), 2011, Vol.47, p.S239-S239

2011

Volltextzugriff (PDF)

Aprepitant: drug–drug interactions in perspective

Annals of oncology, 2010-12, Vol.21 (12), p.2316-2323

2010

Volltextzugriff (PDF)

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

Annals of oncology, 2011-12, Vol.22 (12), p.2546-2555

2011

Volltextzugriff (PDF)

455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period

Annals of oncology, 2023-11, Vol.34, p.S1640

2023

Volltextzugriff (PDF)

188P Pooled analysis of two phase II randomised studies (NorBreast-231 & TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)

Annals of oncology, 2022-05, Vol.33, p.S214-S214

2022

Volltextzugriff (PDF)

295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy

Annals of oncology, 2022-11, Vol.33, p.S1546-S1546

2022

Volltextzugriff (PDF)

5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)

European journal of cancer (1990), 2011, Vol.47, p.S347-S347

2011

Volltextzugriff (PDF)

Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients

Annals of oncology, 2016-10, Vol.27, p.vi499-vi499

2016

Volltextzugriff (PDF)

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Annals of oncology, 2006-09, Vol.17 (9), p.1441-1449

2006

Volltextzugriff (PDF)

Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience

Annals of oncology, 2017-09, Vol.28, p.v560-v561

2017

Volltextzugriff (PDF)

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

European journal of cancer (1990), 2004-10, Vol.40 (15), p.2201-2216

2004

Volltextzugriff (PDF)

Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data

Annals of oncology, 2018-10, Vol.29, p.viii603-viii603

2018

Volltextzugriff (PDF)

291P Perceptions of antibody drug conjugate (ADC)-induced nausea and vomiting: Results of a survey of healthcare providers at ESMO

ESMO open, 2024-05, Vol.9, p.103348, Article 103348

2024

Volltextzugriff (PDF)

II.3 Organisation of the clinical activity of geriatric oncology: report of a SIOG (International Society of Geriatric Oncology) taskforce

Critical reviews in oncology/hematology, 2007-11, Vol.64, p.S13-S13

2007

Volltextzugriff (PDF)

Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool

Annals of oncology, 2016-10, Vol.27, p.vi498-vi498

2016

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

ThemaNeoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(47)
Journals@Ovid Complete
(44)
MEDLINE
(21)
IngentaConnect
(20)
Elsevier ScienceDirect Journals Complete
(19)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(18)
IngentaConnect Journals
(2)
Wiley Online Library - AutoHoldings Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Practical guidance for the management of aromatase inhibitor-associated bone loss

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

F9 Adjuvant chemotherapy for elderly women with breast cancer: immediate benefit and long-term risk

Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

1765P - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)

Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma

2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force

PCN16 Disease Burden and Treatment outcomes in Second-Line Therapy of Patients with Estrogen-Receptor Positive (ER+) Advanced Breast Cancer: A Review of the Literature

3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials

Aprepitant: drug–drug interactions in perspective

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

455P Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period

188P Pooled analysis of two phase II randomised studies (NorBreast-231 & TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)

295TiP Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy

5056 POSTER Analysis of Metastatic Breast Cancer Management Across Europe -the EOS Study (European Observatory & Survey)

Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years’ clinical experience

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data

291P Perceptions of antibody drug conjugate (ADC)-induced nausea and vomiting: Results of a survey of healthcare providers at ESMO

II.3 Organisation of the clinical activity of geriatric oncology: report of a SIOG (International Society of Geriatric Oncology) taskforce

Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool

Aktive Filter

Suchergebnisse filtern